Hepatotoxicity from high-dose methotrexate in primary central nervous system lymphoma
Neuro-Oncology Practice · 12.05.2023 · 10 (3) · 291-300
DOI: 10.1093/nop/npad008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 11.02.2023. Verfasst von Joy C Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Virginia School of Medicine, Charlottesville, Virginia, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
High-dose methotrexate (HDMTX) is a mainstay of primary central nervous system lymphoma (PCNSL) treatment. Transient hepatotoxicity from HDMTX has been characterized in pediatric patients but not in adults. We sought to characterize hepatotoxicity in adult PCNSL patients undergoing HDMTX treatment.
Methods
Retrospective study of 65 PCNSL patients treated at the University of Virginia from 02/01/2002 to 04/01/2020 was performed. Hepatotoxicity was defined using National Cancer Institute Common Toxicity Criteria (CTC) for adverse events, fifth version. High-grade hepatotoxicity was defined as a bilirubin or aminotransferase CTC grade of 3 or 4. Relationships between clinical factors and hepatotoxicity were assessed with logistic regression.
Results
Most patients (90.8%) had a rise of at least one aminotransferase CTC grade during HDMTX treatment. 46.2% had high-grade hepatotoxicity based on aminotransferase CTC grade. No patients developed high-grade bilirubin CTC grades during chemotherapy. Liver enzyme test values decreased to low CTC grade or normal in 93.8% of patients after the conclusion of HDMTX treatment without treatment regimen changes. Prior ALT elevation (P = .0120) was a statistically significant predictor of high-grade hepatotoxicity during treatment. Prior history of hypertension was associated with increased risk of toxic serum methotrexate levels during any cycle (P = .0036).
Conclusions
Hepatotoxicity develops in the majority of HDMTX-treated PCNSL patients. Transaminase values decreased to low or normal CTC grades in almost all patients after treatment, without modification of MTX dosage. Prior ALT elevation may predict patients’ increased hepatotoxicity risk, and hypertension history may be a risk factor for delayed MTX excretion.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Virginia School of Medicine, Charlottesville, Virginia, USA.
- Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
- Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
- Departments of Neurology, Neurological Surgery, and Medicine, University of Virginia Health System, Charlottesville, Virginia, USA.
ORCID-Profile: David Schiff
Zitieren
APA
Zhang, J. C., Stotts, M. J., Horton, B., & Schiff, D. (2023). Hepatotoxicity from high-dose methotrexate in primary central nervous system lymphoma. Neuro-Oncology Practice, 10(3), 291-300. https://doi.org/10.1093/nop/npad008
Vancouver
Zhang JC, Stotts MJ, Horton B, Schiff D. Hepatotoxicity from high-dose methotrexate in primary central nervous system lymphoma. Neuro-Oncology Practice. 2023;10(3):291-300. doi:10.1093/nop/npad008
BibTeX
@article{Zhang2023,
author = {Zhang, Joy C and Stotts, Matthew J and Horton, Bethany and Schiff, David},
title = {Hepatotoxicity from high-dose methotrexate in primary central nervous system lymphoma},
journal = {Neuro-Oncology Practice},
year = {2023},
volume = {10},
number = {3},
pages = {291--300},
doi = {10.1093/nop/npad008}
}
EUVIMED